Corbus Pharmaceuticals (CRBP) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $4.52, +4.39% vs the prior close of $4.33.
- Volume 1.07M shares, 1.1x its 50-day average.
- New SEC filings: 8-K (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
CRBP jumps 4.4% to $4.52. Closed at $4.52, +4.39% vs the prior close of $4.33. Day range $4.22–$4.72, opened at $4.35.
CRBP daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CRBP jumps 4.4% to $4.52
- Closed at $4.52, +4.39% vs the prior close of $4.33. Day range $4.22–$4.72, opened at $4.35.
- Volume was 1.07M shares, 1.1x its 50-day average of 971.56K.
- Price is -45.7% vs its 50-day average ($8.32) and -48.7% vs its 200-day average ($8.82).
- 52-week range $4.22–$20.56; today's close sits at 2% of that range, 78.0% below the 52-week high.
Oct 15, 2026 — CRBP dips 1.8% to $4.33, a 52-week low, 4 down days in a row
- Closed at $4.33, -1.81% vs the prior close of $4.41. Day range $4.23–$4.62, opened at $4.40.
- Volume was 1.09M shares, 1.1x its 50-day average of 954.49K.
- Price is -48.6% vs its 50-day average ($8.42) and -51.0% vs its 200-day average ($8.83).
- 52-week range $4.23–$20.56; today's close sits at 1% of that range, 78.9% below the 52-week high.
- That makes 4 straight losses.
- SEC filings that day: 8-K.
Oct 14, 2026 — CRBP slides 7.7% to $4.41, a 52-week low, 3 down days in a row
- Closed at $4.41, -7.74% vs the prior close of $4.78. Day range $4.37–$4.82, opened at $4.72.
- Volume was 1.34M shares, 1.4x its 50-day average of 932.99K.
- Price is -48.3% vs its 50-day average ($8.53) and -50.2% vs its 200-day average ($8.85).
- 52-week range $4.37–$20.56; today's close sits at 0% of that range, 78.6% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CRBP slides 9.3% to $4.78, a 52-week low
- Closed at $4.78, -9.30% vs the prior close of $5.27. Day range $4.76–$5.26, opened at $5.24.
- Volume was 648.30K shares, 0.7x its 50-day average of 922.66K.
- Price is -44.6% vs its 50-day average ($8.63) and -46.1% vs its 200-day average ($8.87).
- 52-week range $4.76–$20.56; today's close sits at 0% of that range, 76.8% below the 52-week high.
Oct 12, 2026 — CRBP dips 2.0% to $5.27
- Closed at $5.27, -2.04% vs the prior close of $5.38. Day range $5.11–$5.40, opened at $5.35.
- Volume was 1.01M shares, 1.1x its 50-day average of 909.48K.
- Price is -39.5% vs its 50-day average ($8.71) and -40.7% vs its 200-day average ($8.89).
- 52-week range $5.11–$20.56; today's close sits at 1% of that range, 74.4% below the 52-week high.
Oct 9, 2026 — CRBP rises 2.1% to $5.38
- Closed at $5.38, +2.09% vs the prior close of $5.27. Day range $5.17–$5.61, opened at $5.25.
- Volume was 867.90K shares, 1.0x its 50-day average of 894.90K.
- Price is -38.8% vs its 50-day average ($8.79) and -39.6% vs its 200-day average ($8.90).
- 52-week range $5.13–$20.56; today's close sits at 2% of that range, 73.8% below the 52-week high.
Oct 8, 2026 — CRBP slides 4.0% to $5.27, a 52-week low, 6 down days in a row
- Closed at $5.27, -4.01% vs the prior close of $5.49. Day range $5.13–$5.80, opened at $5.80.
- Volume was 1.35M shares, 1.5x its 50-day average of 873.25K.
- Price is -40.5% vs its 50-day average ($8.86) and -40.9% vs its 200-day average ($8.92).
- 52-week range $5.13–$20.56; today's close sits at 1% of that range, 74.4% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — CRBP slides 5.0% to $5.49, a 52-week low, 5 down days in a row
- Closed at $5.49, -5.02% vs the prior close of $5.78. Day range $5.47–$5.80, opened at $5.72.
- Volume was 1.24M shares, 1.5x its 50-day average of 851.52K.
- Price is -38.5% vs its 50-day average ($8.93) and -38.5% vs its 200-day average ($8.93).
- 52-week range $5.47–$20.56; today's close sits at 0% of that range, 73.3% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — CRBP dips 1.2% to $5.78, a 52-week low, 4 down days in a row
- Closed at $5.78, -1.20% vs the prior close of $5.85. Day range $5.65–$5.99, opened at $5.87.
- Volume was 707.40K shares, 0.8x its 50-day average of 844.63K.
- Price is -35.8% vs its 50-day average ($9.00) and -35.4% vs its 200-day average ($8.95).
- 52-week range $5.65–$20.56; today's close sits at 1% of that range, 71.9% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — CRBP slides 4.6% to $5.85, a 52-week low, 3 down days in a row
- Closed at $5.85, -4.57% vs the prior close of $6.13. Day range $5.83–$6.17, opened at $6.17.
- Volume was 793.00K shares, 1.0x its 50-day average of 832.23K.
- Price is -35.5% vs its 50-day average ($9.07) and -34.7% vs its 200-day average ($8.96).
- 52-week range $5.83–$20.56; today's close sits at 0% of that range, 71.5% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — CRBP slides 3.3% to $6.13, a 52-week low
- Closed at $6.13, -3.31% vs the prior close of $6.34. Day range $6.06–$6.68, opened at $6.59.
- Volume was 834.80K shares, 1.0x its 50-day average of 828.33K.
- Price is -32.9% vs its 50-day average ($9.14) and -31.7% vs its 200-day average ($8.97).
- 52-week range $6.06–$20.56; today's close sits at 0% of that range, 70.2% below the 52-week high.
CRBP latest news & SEC filings
Every SEC filing by or about CRBP in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 30, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ben Yong sold 2,000 shares at $7.84 (≈$15.68K) on Sep 14, 2026
- Ben Yong sold 2,000 shares at $7.84 (≈$15.68K) on Sep 14, 2026
- Ben Yong sold 2,000 shares at $7.84 (≈$15.68K) on Sep 14, 2026
- Ben Yong sold 2,000 shares at $7.84 (≈$15.68K) on Sep 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Saxena Nishant C bought 2,600 shares at $9.63 (≈$25.04K) on Aug 11, 2026
- Saxena Nishant C bought 2,600 shares at $9.63 (≈$25.04K) on Aug 11, 2026
- Saxena Nishant C bought 2,600 shares at $9.63 (≈$25.04K) on Aug 11, 2026
- Saxena Nishant C bought 2,600 shares at $9.63 (≈$25.04K) on Aug 11, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cohen Yuval sold 17,000 shares at $10.08 (≈$171.36K) on Aug 7, 2026
- Cohen Yuval sold 17,000 shares at $10.08 (≈$171.36K) on Aug 7, 2026
- Cohen Yuval sold 17,000 shares at $10.08 (≈$171.36K) on Aug 7, 2026
- Cohen Yuval sold 17,000 shares at $10.08 (≈$171.36K) on Aug 7, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Moran Sean F. sold 12,000 shares at $10.08 (≈$120.96K) on Aug 7, 2026
- Moran Sean F. sold 12,000 shares at $10.08 (≈$120.96K) on Aug 7, 2026
- Moran Sean F. sold 12,000 shares at $10.08 (≈$120.96K) on Aug 7, 2026
- Moran Sean F. sold 12,000 shares at $10.08 (≈$120.96K) on Aug 7, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 7, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 7, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$35.04M (prior year -$17.66M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.81 (prior year -$1.44) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade CRBP
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 9, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.87% (largest 9.3%). That is a volatile stock.
- Liquidity: about 858.91K shares (≈$3.88M) trade per day on average.
- 52-week position: $4.52 vs a range of $4.22–$20.56 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 21 sales; latest: Yong Ben sold 2,000 shares on Sep 14, 2026.
- Latest filings: 8-K Oct 15, 2026; 8-K Sep 14, 2026; 10-Q Aug 6, 2026.
- Share count: 19.34M shares outstanding (Aug 4, 2026), +57.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
CRBP market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 4.35 | 4.72 | 4.22 | 4.52 | 1.07M |
| Oct 15, 2026 | 4.40 | 4.62 | 4.23 | 4.33 | 1.09M |
| Oct 14, 2026 | 4.72 | 4.82 | 4.37 | 4.41 | 1.34M |
| Oct 13, 2026 | 5.24 | 5.26 | 4.76 | 4.78 | 648.30K |
| Oct 12, 2026 | 5.35 | 5.40 | 5.11 | 5.27 | 1.01M |
| Oct 9, 2026 | 5.25 | 5.61 | 5.17 | 5.38 | 867.90K |
| Oct 8, 2026 | 5.80 | 5.80 | 5.13 | 5.27 | 1.35M |
| Oct 7, 2026 | 5.72 | 5.80 | 5.47 | 5.49 | 1.24M |
| Oct 6, 2026 | 5.87 | 5.99 | 5.65 | 5.78 | 707.40K |
| Oct 5, 2026 | 6.17 | 6.17 | 5.83 | 5.85 | 793.00K |
| Oct 2, 2026 | 6.59 | 6.68 | 6.06 | 6.13 | 834.80K |
| Oct 1, 2026 | 6.80 | 6.82 | 6.25 | 6.34 | 802.60K |
| Sep 30, 2026 | 6.75 | 6.88 | 6.57 | 6.82 | 507.00K |
| Sep 29, 2026 | 6.93 | 7.05 | 6.59 | 6.63 | 785.80K |
| Sep 28, 2026 | 7.12 | 7.18 | 6.88 | 6.92 | 932.00K |
| Sep 25, 2026 | 7.50 | 7.59 | 6.97 | 7.14 | 708.20K |
| Sep 24, 2026 | 7.69 | 7.76 | 7.12 | 7.45 | 757.80K |
| Sep 23, 2026 | 7.83 | 7.98 | 7.66 | 7.74 | 787.30K |
| Sep 22, 2026 | 7.73 | 7.95 | 7.61 | 7.88 | 452.80K |
| Sep 21, 2026 | 7.51 | 7.79 | 7.42 | 7.65 | 499.70K |
About Corbus Pharmaceuticals
Corbus Pharmaceuticals (CRBP) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NORWOOD, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1595097.
CRBP board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Anne Altmeyer | Director | Jun 11, 2026 |
| Yong Ben | Director | Sep 15, 2026 |
| Yuval Cohen | Chief Executive Officer | Aug 10, 2026 |
| Rachelle Suzanne Jacques | Director | May 21, 2026 |
| John Kenneth Jenkins | Director | Jun 11, 2026 |
| Winston Kung | Director | Jun 11, 2026 |
| Brent Pfeiffenberger | Director | May 21, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Yuval Cohen | Chief Executive Officer | Aug 10, 2026 |
| Ian Hodgson | Chief Operating Officer | Feb 18, 2026 |
| Sean F. Moran | Chief Financial Officer | Aug 10, 2026 |
| Leonardo Viana Nicacio | Chief Medical Officer | Aug 17, 2026 |
| Nishant C Saxena | Chief Business Officer | Aug 12, 2026 |
| Dominic Smethurst | Chief Medical Officer | Mar 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 14, 2026 | Yong Ben | Sale | 2,000 | $7.84 |
| Sep 14, 2026 | Yong Ben | Sale | 2,000 | $7.84 |
| Sep 14, 2026 | Yong Ben | Sale | 2,000 | $7.84 |
| Sep 14, 2026 | Yong Ben | Sale | 2,000 | $7.84 |
| Aug 11, 2026 | Nishant C Saxena | Buy | 2,600 | $9.63 |
| Aug 11, 2026 | Nishant C Saxena | Buy | 2,600 | $9.63 |
| Aug 11, 2026 | Nishant C Saxena | Buy | 2,600 | $9.63 |
| Aug 11, 2026 | Nishant C Saxena | Buy | 2,600 | $9.63 |
| Aug 7, 2026 | Sean F. Moran | Sale | 12,000 | $10.08 |
| Aug 7, 2026 | Sean F. Moran | Sale | 12,000 | $10.08 |
| Aug 7, 2026 | Sean F. Moran | Sale | 12,000 | $10.08 |
| Aug 7, 2026 | Sean F. Moran | Sale | 12,000 | $10.08 |
| Aug 7, 2026 | Yuval Cohen | Sale | 17,000 | $10.08 |
| Aug 7, 2026 | Yuval Cohen | Sale | 17,000 | $10.08 |
| Aug 7, 2026 | Yuval Cohen | Sale | 17,000 | $10.08 |
CRBP financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-78.54M | -5.90 | $-64.49M |
| Dec 31, 2024 | — | $-40.21M | -3.68 | $-41.79M |
| Dec 31, 2023 | — | $-44.60M | -10.31 | $-36.10M |
| Dec 31, 2022 | $0 | $-42.35M | -10.15 | $-37.54M |
| Dec 31, 2021 | $881.71K | $-45.64M | -11.15 | $-48.18M |
Latest balance sheet: total assets $126.99M, total liabilities $24.75M, cash $23.37M (as of Jun 30, 2026).
CRBP earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $9.74 |
| May 12, 2026 | 8-K Item 2.02 (results) | $11.43 |
| Mar 9, 2026 | 8-K Item 2.02 (results) | $9.55 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $11.19 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $8.90 |
| May 6, 2025 | 8-K Item 2.02 (results) | $6.25 |
| Mar 11, 2025 | 8-K Item 2.02 (results) | $6.88 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $18.52 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Mar 12, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CRBP
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.